242 GSK Annual Report 2017 Notes to the company balance sheet UK GAAP including FRS 101 Reduced Disclosure Framework continued I Provisions for liabilities 2017 2016 m m At 1 January 23 40 Exchange adjustments 3 13 Charge for the year 52 78 Utilised 45 108 At 31 December 27 23 The provisions relate to a number of legal and other disputes in which the company is currently involved.
J Other non-current liabilities 2017 2016 m m Contingent consideration payable 238 534 238 534 The contingent consideration relates to the amount payable for the acquisition in 2015 of the Novartis Vaccines portfolio.
The current year liability is included within Trade and other payables.
K Share capital and share premium account Share premium Ordinary Shares of 25p each account Number m m Share capital authorised At 31 December 2016 10,000,000,000 2,500 At 31 December 2017 10,000,000,000 2,500 Share capital issued and fully paid At 1 January 2016 5,361,307,647 1,340 2,831 Issued under employee share schemes 7,008,415 2 87 Treasury shares transferred to the ESOP Trust 36 At 31 December 2016 5,368,316,062 1,342 2,954 Issued under employee share schemes 4,237,758 1 55 Treasury shares transferred to the ESOP Trust 10 At 31 December 2017 5,372,553,820 1,343 3,019 31 December 31 December 2017 2016 000 000 Number of shares issuable under employee share schemes 38,647 71,382 Number of unissued shares not under option 4,588,799 4,560,302 At 31 December 2017, of the issued share capital, 66,696,677 shares were held in the ESOP Trusts, 414,605,950 shares were held as Treasury shares and 4,891,251,193 shares were in free issue.
All issued shares are fully paid.
The nominal, carrying and market values of the shares held in the ESOP Trusts are disclosed in Note 43, Employee share schemes.
L Retained earnings The profit of GlaxoSmithKline plc for the year was 9,893 million 2016 111 million loss, which after dividends of 3,906 million 2016 4,850 million, gave a retained profit of 5,987 million 2016 4,961 million loss.
No Treasury shares were purchased in the year 2016 nil.
After the effect of the 581 million Treasury shares transferred to a subsidiary company 2016 466 million, retained earnings at 31 December 2017 stood at 22,106 million 2016 15,538 million, of which 4,096 million was unrealised 2016 4,096 million.
In addition, the 10 billion dividend received by the company during 2017 will not be distributable until after the 2017 Annual Report is filed during April 2018.
M Group companies See pages 276 to 286 for a complete list of subsidiaries, associates and joint ventures, which forms part of these financial statements.
